IRLAB Therapeutics AB announced that the nomination committee ahead of the annual general meeting (AGM) 2024 have been appointed. The three largest shareholders or groups of shareholders have now appointed their representatives, thus the nomination committee ahead of the AGM 2024 has the following members: Clas Sonesson, Chief Scientific Officer (CSO) at IRLAB and one of IRLAB?s founders. Appointed by a group of shareholders that consists of the company?s founders representing about 14% of shares and votes; Daniel Johnsson, entrepreneur, business developer, investor, and board member of IRLAB.

Appointed by a group of shareholders that consists of the company?s founders representing about 13% of shares and votes; and Anders Vedin, background from executive positions at global pharmaceutical companies and previous Chair of the Board of IRLAB, appointed by a group of shareholders representing about 13% of shares and votes; and Carola Lemne, Chair of the Board of IRLAB Therapeutics AB. The members of the nomination committee have been appointed by owners in IRLAB Therapeutics AB who represent a total of about 40% of the total number of shares and votes in IRLAB Therapeutics AB as per August 31, 2023.